Iryna Drozd Repare Therapeutics ( NASDAQ: RPTX ) said it has received FDA fast track designation for its drug lunresertib in combination with camonsertib for the treatment of certain types of platinum-resistant ovarian cancer. Lunresertib with camonsertib is currently being tested in a Phase 1 dose expansion trial for the treatment of ovarian and endometrial cancers harboring CCNE1amplication or FBXW7 or PPP2R1A mutations. Data from the dose expansion cohorts is expected in Q4, according to the company .
The combination was previously granted FDA fast track status for the treatment of CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer. More on Repare Therapeutics Repare Therapeutics appoints Steven Stein to its board of directors Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeutics.
